FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793364080> ?p ?o ?g. }

• W2793364080 endingPage "e180013" @default.
• W2793364080 startingPage "e180013" @default.
• W2793364080 abstract "Therapeutic options are needed for patients with advanced gastric cancer whose disease has progressed after 2 or more lines of therapy.To evaluate the safety and efficacy of pembrolizumab in a cohort of patients with previously treated gastric or gastroesophageal junction cancer.In the phase 2, global, open-label, single-arm, multicohort KEYNOTE-059 study, 259 patients in 16 countries were enrolled in a cohort between March 2, 2015, and May 26, 2016. Median (range) follow-up was 5.8 (0.5-21.6) months.Patients received pembrolizumab, 200 mg, intravenously every 3 weeks until disease progression, investigator or patient decision to withdraw, or unacceptable toxic effects.Primary end points were objective response rate and safety. Objective response rate was assessed by central radiologic review per Response Evaluation Criteria in Solid Tumors, version 1.1, in all patients and those with programmed cell death 1 ligand 1 (PD-L1)-positive tumors. Expression of PD-L1 was assessed by immunohistochemistry. Secondary end points included response duration.Of 259 patients enrolled, most were male (198 [76.4%]) and white (200 [77.2%]); median (range) age was 62 (24-89) years. Objective response rate was 11.6% (95% CI, 8.0%-16.1%; 30 of 259 patients), with complete response in 2.3% (95% CI, 0.9%-5.0%; 6 of 259 patients). Median (range) response duration was 8.4 (1.6+ to 17.3+) months (+ indicates that patients had no progressive disease at their last assessment). Objective response rate and median (range) response duration were 15.5% (95% CI, 10.1%-22.4%; 23 of 148 patients) and 16.3 (1.6+ to 17.3+) months and 6.4% (95% CI, 2.6%-12.8%; 7 of 109 patients) and 6.9 (2.4 to 7.0+) months in patients with PD-L1-positive and PD-L1-negative tumors, respectively. Forty-six patients (17.8%) experienced 1 or more grade 3 to 5 treatment-related adverse events. Two patients (0.8%) discontinued because of treatment-related adverse events, and 2 deaths were considered related to treatment.Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment. Durable responses were observed in patients with PD-L1-positive and PD-L1-negative tumors. Further study of pembrolizumab for this group of patients is warranted.clinicaltrials.gov Identifier: NCT02335411." @default.
• W2793364080 created "2018-03-29" @default.
• W2793364080 creator A5001115937 @default.
• W2793364080 creator A5010492722 @default.
• W2793364080 creator A5013287848 @default.
• W2793364080 creator A5015799240 @default.
• W2793364080 creator A5019473289 @default.
• W2793364080 creator A5019734570 @default.
• W2793364080 creator A5024904484 @default.
• W2793364080 creator A5027852679 @default.
• W2793364080 creator A5030853533 @default.
• W2793364080 creator A5031702425 @default.
• W2793364080 creator A5045186065 @default.
• W2793364080 creator A5049314303 @default.
• W2793364080 creator A5050481393 @default.
• W2793364080 creator A5058524907 @default.
• W2793364080 creator A5064264391 @default.
• W2793364080 creator A5065124595 @default.
• W2793364080 creator A5065784545 @default.
• W2793364080 creator A5068026508 @default.
• W2793364080 creator A5070411005 @default.
• W2793364080 creator A5072170693 @default.
• W2793364080 creator A5072171783 @default.
• W2793364080 creator A5073330859 @default.
• W2793364080 creator A5078338048 @default.
• W2793364080 creator A5078820101 @default.
• W2793364080 creator A5079737300 @default.
• W2793364080 creator A5084496860 @default.
• W2793364080 creator A5084809433 @default.
• W2793364080 creator A5089202777 @default.
• W2793364080 creator A5090604653 @default.
• W2793364080 date "2018-05-10" @default.
• W2793364080 modified "2023-10-15" @default.
• W2793364080 title "Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer" @default.
• W2793364080 cites W1128365645 @default.
• W2793364080 cites W1757407923 @default.
• W2793364080 cites W1809627231 @default.
• W2793364080 cites W1875373156 @default.
• W2793364080 cites W2097820456 @default.
• W2793364080 cites W2100158834 @default.
• W2793364080 cites W2104631255 @default.
• W2793364080 cites W2104759721 @default.
• W2793364080 cites W2106787323 @default.
• W2793364080 cites W2111237964 @default.
• W2793364080 cites W2114489245 @default.
• W2793364080 cites W2114734455 @default.
• W2793364080 cites W2118471749 @default.
• W2793364080 cites W2126547130 @default.
• W2793364080 cites W2132871418 @default.
• W2793364080 cites W2137591261 @default.
• W2793364080 cites W2139248078 @default.
• W2793364080 cites W2198093519 @default.
• W2793364080 cites W2308363199 @default.
• W2793364080 cites W2342599605 @default.
• W2793364080 cites W2345415641 @default.
• W2793364080 cites W2347070489 @default.
• W2793364080 cites W2401455386 @default.
• W2793364080 cites W2409346424 @default.
• W2793364080 cites W2416791964 @default.
• W2793364080 cites W2560367415 @default.
• W2793364080 cites W2570159314 @default.
• W2793364080 cites W2572174216 @default.
• W2793364080 cites W2587433409 @default.
• W2793364080 cites W2618726964 @default.
• W2793364080 cites W2655262992 @default.
• W2793364080 cites W2747213610 @default.
• W2793364080 cites W2763064222 @default.
• W2793364080 cites W2917837889 @default.
• W2793364080 cites W4210975948 @default.
• W2793364080 cites W4211007657 @default.
• W2793364080 cites W4250855637 @default.
• W2793364080 cites W4252702579 @default.
• W2793364080 doi "https://doi.org/10.1001/jamaoncol.2018.0013" @default.
• W2793364080 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5885175" @default.
• W2793364080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29543932" @default.
• W2793364080 hasPublicationYear "2018" @default.
• W2793364080 type Work @default.
• W2793364080 sameAs 2793364080 @default.
• W2793364080 citedByCount "1219" @default.
• W2793364080 countsByYear W27933640802018 @default.
• W2793364080 countsByYear W27933640802019 @default.
• W2793364080 countsByYear W27933640802020 @default.
• W2793364080 countsByYear W27933640802021 @default.
• W2793364080 countsByYear W27933640802022 @default.
• W2793364080 countsByYear W27933640802023 @default.
• W2793364080 crossrefType "journal-article" @default.
• W2793364080 hasAuthorship W2793364080A5001115937 @default.
• W2793364080 hasAuthorship W2793364080A5010492722 @default.
• W2793364080 hasAuthorship W2793364080A5013287848 @default.
• W2793364080 hasAuthorship W2793364080A5015799240 @default.
• W2793364080 hasAuthorship W2793364080A5019473289 @default.
• W2793364080 hasAuthorship W2793364080A5019734570 @default.
• W2793364080 hasAuthorship W2793364080A5024904484 @default.
• W2793364080 hasAuthorship W2793364080A5027852679 @default.
• W2793364080 hasAuthorship W2793364080A5030853533 @default.
• W2793364080 hasAuthorship W2793364080A5031702425 @default.
• W2793364080 hasAuthorship W2793364080A5045186065 @default.
• W2793364080 hasAuthorship W2793364080A5049314303 @default.

• next